Phalanx Biotech Group

Phalanx Biotech Group, founded in 2002 in Hsinchu, Taiwan, focuses on genetic testing solutions.Phalanx Biotech Group specializes in advanced genetic testing technologies, focusing on high-density gene microarray chips and next-generation sequencing. Their key offerings include non-invasive prenatal testing (NIPT) for fetal chromosomal abnormalities, genetic disease carrier screening, and newborn screening for conditions such as spinal muscular atrophy and congenital cytomegalovirus. They serve healthcare providers, hospitals, and clinics, with a strong presence in Taiwan and expanding influence in other Asian markets.Phalanx Biotech Group generates revenue through direct-to-consumer and B2B transactions, primarily with healthcare institutions and clinics that utilize their genetic testing services. They provide specific tests, including prenatal genetic screening and cancer risk assessments, under contracts based on volume and service offerings.Phalanx Biotech Group plans to expand its product line and market reach, with new products in development aimed at enhancing genetic testing capabilities. Specific markets targeted for expansion include Southeast Asia, anticipated to commence by 2025.8 mn will support these initiatives, particularly in scaling operations and enhancing R&D for new product launches.

1. Series B

   Mar 1, 2004

   Amount

   $12M

   Investors

   Locked